Azeliragon, a clinically tested RAGE inhibitor, exhibits potent anti-MRSA activity by perturbing membrane phospholipids and interacting with the cell-wall enzyme MurA. This multi-mechanism action supports its repurposing as a promising candidate against MRSA.
- Junhua Ma
- Yuqing Xia
- Zewen Wen
